KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Uncomplicated Plasmodium Falciparum Malaria
Conditions
Acute Uncomplicated Plasmodium Falciparum Malaria
Trial Timeline
Aug 2, 2017 → Jun 28, 2021
NCT ID
NCT03167242About KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation is a phase 2 stage product being developed by Novartis for Acute Uncomplicated Plasmodium Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT03167242. Target conditions include Acute Uncomplicated Plasmodium Falciparum Malaria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03167242 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Uncomplicated Plasmodium Falciparum Malaria